ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för dactolisib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

25 träffar

Bibliografisk träff 2013-02-12

The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor.

Sano T, Takeuchi S, Nakagawa T, Ishikawa D, Nanjo S, Yamada T, Nakamura T, Matsumoto K, Yano S.

Int J Cancer · research support, non-u.s. gov't; journal article · DOI 10.1002/ijc.28034

Bibliografisk träff 2013-02-12

Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors.

Figlin RA, Kaufmann I, Brechbiel J.

Int J Cancer · research support, non-u.s. gov't; review; journal article · DOI 10.1002/ijc.28023

Bibliografisk träff 2013-02-01

Studies of NVP-BEZ235 in melanoma.

Sznol JA, Jilaveanu LB, Kluger HM.

Curr Cancer Drug Targets · research support, non-u.s. gov't; review; journal article · DOI 10.2174/1568009611313020006

Bibliografisk träff 2013-01-23

Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models.

Issa A, Gill JW, Heideman MR, Sahin O, Wiemann S, Dey JH, Hynes NE.

Breast Cancer Res · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1186/bcr3379

Bibliografisk träff 2013-01-12

Radiosensitization of prostate cancer cells by the dual PI3K/mTOR inhibitor BEZ235 under normoxic and hypoxic conditions.

Potiron VA, Abderrahmani R, Giang E, Chiavassa S, Di Tomaso E, Maira SM, Paris F, Supiot S.

Radiother Oncol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.radonc.2012.11.014

Bibliografisk träff 2013-01-08

PAK1 mediates resistance to PI3K inhibition in lymphomas.

Walsh K, McKinney MS, Love C, Liu Q, Fan A, Patel A, Smith J, Beaven A, Jima DD, Dave SS.

Clin Cancer Res · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1078-0432.ccr-12-1060

Bibliografisk träff 2012-11-01

Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer.

Venkannagari S, Fiskus W, Peth K, Atadja P, Hidalgo M, Maitra A, Bhalla KN.

Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.724

Bibliografisk träff 2012-10-15

Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy.

Lin SF, Huang YY, Lin JD, Chou TC, Hsueh C, Wong RJ.

PLoS One · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0046726

Bibliografisk träff 2012-09-18

Inhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.

Cerniglia GJ, Karar J, Tyagi S, Christofidou-Solomidou M, Rengan R, Koumenis C, Maity A.

Mol Pharmacol · research-article; journal article; research support, n.i.h., extramural · DOI 10.1124/mol.112.080408

Bibliografisk träff 2012-08-31

Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma.

Doghman M, Lalli E.

Mol Cell Endocrinol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.mce.2012.08.014

Bibliografisk träff 2012-08-25

NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy.

Civallero M, Cosenza M, Marcheselli L, Pozzi S, Sacchi S.

Expert Opin Investig Drugs · journal article · DOI 10.1517/13543784.2012.719871

Bibliografisk träff 2012-08-16

Dual PI3K/mTOR inhibitor NVP-BEZ235 suppresses hypoxia-inducible factor (HIF)-1α expression by blocking protein translation and increases cell death under hypoxia.

Karar J, Cerniglia GJ, Lindsten T, Koumenis C, Maity A.

Cancer Biol Ther · research-article; journal article; research support, n.i.h., extramural · DOI 10.4161/cbt.21144

Bibliografisk träff 2012-08-03

Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.

Wöhrle FU, Halbach S, Aumann K, Schwemmers S, Braun S, Auberger P, Schramek D, Penninger JM, Laßmann S, Werner M, Waller CF, Pahl HL, Zeiser R, Daly RJ, Brummer T.

Leukemia · research support, non-u.s. gov't; journal article; research support, n.i.h., extramural · DOI 10.1038/leu.2012.222

Bibliografisk träff 2012-06-08

Determination of NVP-BEZ235, a dual PI3K and mTOR inhibitor, in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography with fluorescence detection.

Lin F, Chandrasekaran G, de Gooijer MC, Beijnen JH, van Tellingen O.

J Chromatogr B Analyt Technol Biomed Life Sci · journal article · DOI 10.1016/j.jchromb.2012.05.033

Bibliografisk träff 2012-05-25

Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.

Shoji K, Oda K, Kashiyama T, Ikeda Y, Nakagawa S, Sone K, Miyamoto Y, Hiraike H, Tanikawa M, Miyasaka A, Koso T, Matsumoto Y, Wada-Hiraike O, Kawana K, Kuramoto H, McCormick F, Aburatani H, Yano T, Kozuma S, Taketani Y.

PLoS One · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0037431

Bibliografisk träff 2012-05-05

The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.

Kim A, Park S, Lee JE, Jang WS, Lee SJ, Kang HJ, Lee SS.

Leuk Res · journal article · DOI 10.1016/j.leukres.2012.02.010

Bibliografisk träff 2012-03-27

NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity.

Fokas E, Yoshimura M, Prevo R, Higgins G, Hackl W, Maira SM, Bernhard EJ, McKenna WG, Muschel RJ.

Radiat Oncol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/1748-717x-7-48

Bibliografisk träff 2012-03-13

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition.

Haagensen EJ, Kyle S, Beale GS, Maxwell RJ, Newell DR.

Br J Cancer · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/bjc.2012.70

Bibliografisk träff 2012-03-08

Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells.

Blaser B, Waselle L, Dormond-Meuwly A, Dufour M, Roulin D, Demartines N, Dormond O.

BMC Cancer · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/1471-2407-12-86

Bibliografisk träff 2012-03-01

The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.

Awasthi N, Yen PL, Schwarz MA, Schwarz RE.

J Cell Biochem · journal article · DOI 10.1002/jcb.23405

Bibliografisk träff 2012-02-01

The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells.

Schult C, Dahlhaus M, Glass A, Fischer K, Lange S, Freund M, Junghanss C.

Anticancer Res · research support, non-u.s. gov't; journal article

Bibliografisk träff 2012-01-27

The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophils.

Blatt K, Herrmann H, Mirkina I, Hadzijusufovic E, Peter B, Strommer S, Hoermann G, Mayerhofer M, Hoetzenecker K, Klepetko W, Ghanim V, Marth K, Füreder T, Wacheck V, Valenta R, Valent P.

PLoS One · research support, non-u.s. gov't; research-article; evaluation study; journal article · DOI 10.1371/journal.pone.0029925

Bibliografisk träff 2012-01-01

Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma.

Chanthery YH, Gustafson WC, Itsara M, Persson A, Hackett CS, Grimmer M, Charron E, Yakovenko S, Kim G, Matthay KK, Weiss WA.

Sci Transl Med · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1126/scitranslmed.3002977

Bibliografisk träff 2012-01-01

The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses.

Mukherjee B, Tomimatsu N, Amancherla K, Camacho CV, Pichamoorthy N, Burma S.

Neoplasia · research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1593/neo.111512

Bibliografisk träff 2011-12-07

The phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 is effective in inhibiting regrowth of tumour cells after cytotoxic therapy.

Hernlund E, Olofsson MH, Fayad W, Fryknäs M, Lesiak-Mieczkowska K, Zhang X, Brnjic S, Schmidt V, D'Arcy P, Sjöblom T, De Milito A, Larsson R, Linder S.

Eur J Cancer · journal article · DOI 10.1016/j.ejca.2011.11.013